Health at a Glance: Europe 2012 presents key indicators of health and health systems in 35 European countries, including the 27 European Union member states, 5 candidate countries and 3 European Free Trade Association countries.
The selection of indicators is based largely on the European Community Health Indicators (ECHI) shortlist, a set of indicators that has been developed to guide the reporting of health statistics in the European Union (ECHIM, 2012). It is complemented by additional indicators on health expenditure and quality of care in the related chapters.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2013-03-05 09:09:532015-10-12 17:08:29Health at a Glance Europe 2012
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2012-12-17 22:09:182015-03-16 20:13:58Documentos CDC de ayuda para investigar casos agudos de hepatitis.
This MMWR supplement summarizes the deliberations of CDC/ATSDR scientists and managers who met in September 2009 in Atlanta as part of the 2009 Consultation on CDC/ATSDR’s Vision for Public Health Surveillance in the 21st Century. The meeting was convened to reflect on domestic and global public health surveillance practice and to recommend a strategic framework to advance public health surveillance to meet continuing and new challenges. The first report is an adaptation of the keynote address for the meeting, which summarized the history of public health surveillance, the need to reassess its usefulness, the rationale for topics selected for discussion, and the charge to participants. Subsequent reports summarize the discussions of workgroups that addressed specific topics in surveillance science and practices.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2012-08-29 08:02:372013-07-16 11:01:19CDC’s Vision for Public Health Surveillance in the 21st Century
Since mid-2011, a substantial rise in pertussis cases has been reported in the state of Washington. In response to this increase, the Washington State Secretary of Health declared a pertussis epidemic on April 3, 2012. By June 16, the reported number of cases in Washington in 2012 had reached 2,520 (37.5 cases per 100,000 residents), a 1,300% increase compared with the same period in 2011 and the highest number of cases reported in any year since 1942.
To assess clinical, epidemiologic, and laboratory factors associated with this increase, all pertussis cases reported during January 1–June 16, 2012, were reviewed. Consistent with national trends, high rates of pertussis were observed among infants aged <1 year and children aged 10 years. However, the incidence in adolescents aged 13–14 years also was increased, despite high rates of vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine, suggesting early waning of immunity.
The focus of prevention and control efforts is the protection of infants and others at greatest risk for severe disease and improving vaccination coverage in adolescents and adults, especially those who are pregnant. Pertussis vaccination remains the single most effective strategy for prevention of infection.
VariZIG (Cangene Corporation, Winnipeg, Canada) is
the only varicella zoster immune globulin preparation available in the United States for postexposure prophylaxis of varicella in persons at high risk for severe disease who lack evidence of immunity to varicella and are ineligible for varicella vaccine. VariZIG is available in the United States through an investigational new drug (IND) application expanded access protocol (1). VariZIG is a purified immune globulin preparation made from human plasma containing high levels of anti–varicella zoster virus antibodies (immunoglobulin G). In May 2011, the Food and Drug Administration (FDA) approved an extended period for administering VariZIG. The period after exposure to varicella zoster virus during which a patient may receive VariZIG, which had been 96 hours (4 days), is now 10 days (1). VariZIG should be administered as soon as possible after exposure (1). Leer más
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2012-05-03 12:16:092015-03-16 20:14:50FDA Approval of an Extended Period for Administering VariZIG for Postexposure Prophylaxis of Varicella
Utilizamos cookies propias y de terceros para mejorar nuestro servicio y mostrar contenido relacionado con tus preferencias mediante el análisis de los hábitos de navegación.<br /> Si continúas navegando, consideramos que aceptas su uso. Más información
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
